Expression of CD133 in various premalignant and proliferative lesions

• Main Authors: Rahmi Amtha (Author), Indrayadi Gunardi (Author), Ferry Sandra (Author), Diah Savitri Ernawati (Author)
• Format: Book
• Published: Universitas Airlangga, 2015-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 1978-3728; 2442-9740; 10.20473/j.djmkg.v48.i2.p64-68
• Keywords: CD133; premalignant; proliferative; Dentistry; RK1-715
• Source: Dental Journal, Vol 48, Iss 2, Pp 64-68 (2015)

<span style="font-family: Tribune-Bold; font-size: 10pt; color: #231f20; font-style: normal; font-variant: normal;"><strong>Background:</strong><span style="font-family: Tribune-Italic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em> In Jakarta, oral squamous cell carcinoma (OSCC) usually detected in late stage with very low survival rate ofabout </em><span style="font-family: Tribune-Italic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>1.1 years. OSCC may be preceded by premalignant lesion, so that early detection of the lesion may decrease the mortality rate due to </em><span style="font-family: Tribune-Italic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>oral malignancy. CD133 is a hematopoietic stem cell that play role in tissue regeneration, inflammation and tumor. Upregulated of </em><span style="font-family: Tribune-Italic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>CD133 was reported on tumor progression. </em><span style="font-family: Tribune-Bold; font-size: 10pt; color: #231f20; font-style: normal; font-variant: normal;"><strong>Purpose:</strong><span style="font-family: Tribune-Italic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em> The aim of study is to determine circulating CD133 expression on premalignant </em><span style="font-family: Tribune-Italic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>(PML) and proliferative (PL) lesion. </em><span style="font-family: Tribune-Bold; font-size: 10pt; color: #231f20; font-style: normal; font-variant: normal;"><strong>Method:</strong><span style="font-family: Tribune-Italic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em> Observational research was carried out on patients who seek treatment of PML and PL </em><span style="font-family: Tribune-Italic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>at Oral Medicine clinic. CD133 was taken from peripheral blood serum, examined using PCR. Data was analyzed by Chi square test. </em><span style="font-family: Tribune-Bold; font-size: 10pt; color: #231f20; font-style: normal; font-variant: normal;"><strong>Result:</strong><span style="font-family: Tribune-Italic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em> 15 subjects (each of five subjects for PML, PL and control) consist of 40% male and 60% female. Age group of above 41 years </em><span style="font-family: Tribune-Italic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>old was most affected PML and PL (66.7%). Tongue is common site for oral lesion (40%). There is a significant different of circulating </em><span style="font-family: Tribune-Italic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>CD133 rate among all groups lesion (p=0.039). </em><span style="font-family: Tribune-Bold; font-size: 10pt; color: #231f20; font-style: normal; font-variant: normal;"><strong>Conclusion: </strong><span style="font-family: Tribune-Italic; font-size: 9pt; color: #231f20; font-style: normal; font-variant: normal;"><em>CD133 express differently in premalignant and proliferative lesions.</em></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span>